Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Christopher Bunka is Director at Lexaria Bioscience. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jul 30, 2025, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
1 buy, median −2.2 pts vs S&P 500, beat it 0 of 1 time.
Average −2.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jul 30, 2025 to Jul 30, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.8 pts (median, against the S&P 500).
Lexaria BioscienceLEXX
2 disclosures · Jul 2025 · 2 bought
Jul 29, 2025Bought~$14Kdisclosed Jul 30
DetailsOfficial recordJul 30, 2025Bought~$11K
DetailsAs of the latest filing on , Christopher Bunka reported holding 555,455 shares of Lexaria Bioscience (LEXX), worth about $2.49M at the last close of $4 (Nov 19, 2026): 273,543 held directly and 281,912 through a private holding company.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Lexaria Bioscience LEXX | 555,455 | 274K direct · 282K private holding company | $4 | $2.49M | Mar 17, 2026 |
Is this Christopher Bunka’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Christopher Bunka reported 625 open-market purchases and 0 sales here, 2006 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Christopher Bunka bought shares on the open market in 12 different years since 2006.
Christopher Bunka reported 625 open-market purchases and 0 sales since 2006; purchases in 12 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $25K2×2 trades | — |
| 2022 | $78K2×2 trades | — |
| 2020 | $40K10×10 trades | — |
| 2016 | $71K49×49 trades | — |
| 2015 | $602K309×309 trades | — |
| 2014 | $116K29×29 trades | — |
| 2012 | $5.7K6×6 trades | — |
| 2011 | $223K74×74 trades | — |
| 2010 | $133K71×71 trades | — |
| 2009 | $148K37×37 trades | — |
| 2008 | $77K35×35 trades | — |
| 2006 | $583K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Mar 17, 2026, Christopher Bunka reported holding 555,455 shares of Lexaria Bioscience (LEXX), of which 281,912 are held indirectly. At the last close of $4 on Nov 19, 2026, that is about $2.49M. This is the stake disclosed in filings, not a net worth.
No public filing gives Christopher Bunka's net worth. What SEC Form 4 shows is the stock stake: 555,455 shares of Lexaria Bioscience (LEXX), about $2.49M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Christopher Bunka bought shares on the open market in 12 different years since 2006.
In SEC filings since 2006: the latest open-market purchase is from 2025; no open-market sale is on record.
Lexaria Bioscience (LEXX), from 2006 to 2025: 625 purchases and 0 sales.